WPC ^<\}Š =D| r4b-ç6t4D%0Ԑ+Fiҷ/q'!7JwpV|/!ZAC Biۄ#]ɔ7|tNi,#8yxEx*8\-^$|Z]۾-֬DDeUzX|eo^Hd!oB) Uztl'V_~,@3|ZВֿUܔPSJ"ϩ͌u 2(*"S8,O,zC_tqenՅ* J\KU+f TVAf= I!RN-%JvZ8vЊ5EMb x^jL!)$T@ܲx h\{-tΉ  EW #UN % 0: 1u) 72 0rcUN3^ w4 mhp LaserJet 1300 PCL 5e,,,,0(9 Z6Times New Roman RegularX($USUS.,3#37=CIQYag1.a.i.(1)(a)(i)1)a)i)(;3$2#  0  .3  0  (9 Z 6Times New Roman RegularG2 a1:i+003|xU !USUS.,  _XXHH  Unit9:OtherBloodGroupSystems  X u (#33 XpXXX "3"  3t2#  1  .3  0    Define"highincidence"or"public"and lowincidenceor"private"antigens.0h$$0!h$h$0$!$!$0@$0%0%0@$%%0@$x%x%0@$ % %0@$0%0%3t݌0$$$$ Ќ  "3"  3-2#  2  .3  0    Describetheimportanceofknowingtheserologicbehaviorandcharacteristicsofthemajorblood  groupantibodies.3-Z݌$$ Ќ  __"3"  32#  3  .3  0    Foreachofthefollowingbloodgroupstatethe_followng_:antigens,mostcommonantibodyclass  produced,abilitytocause_HDN_Ԁand_HTR_phaseofreactivity,andclinicalsignificance3݌$$ Ќ  0    I/I,Lutheran,Lewis,_Kell_,P,Duffy,MN,_Kidd_,_S,s_ԀandUt$$ "3"  32#  4  .3  0    Describethedevelopmentofthe_i_ԀandIantigensandstatethesourceofcellswiththemost_i_  ` antigen.3݌ L $$ Ќ  "3"  3 2#  5  .3  0    ListthediseasesassociatedwithantiIandanti_i_.3 C ݌ 8 $$ Ќ  "3"  33 2#  6  .3  0    DescribetheserologicaltestingutilizedtoconfirmthespecificityofI/_i_Ԁantibodies.33 ` ݌| $ $$ Ќ  "3"  3s 2#  7  .3  0    DescribethedevelopmentoftheLewisantigensontotheredbloodcells.3s ݌h  $$ Ќ  "3"  3 2#  8  .3  0    DescribeLewisantigenandantibodyactivityduringpregnancy.3 ݌T $$ Ќ  "3"  3 2#  9  .3  0    StatetheprincipleoftheLewisneutralizationtest.3 ݌@ $$ Ќ  "3 "  32#  10  .3  0    Explainhowaperson'ssecretorstatusinfluencestheirLewisphenotype,givetheLewis ,  phenotypeofasecretorand_nonsecretor_Ԁandstatewhatpercentageofthepopulationare3݌$$ Ќ    _secretors_.  "3 "  32#  11  .3  0    Statetheantibodyclass,reactivityandclinicalsignificanceofLewisantibodies.3݌$$ Ќ  "3 "  32#  12  .3  0    DescribethecurrenttransfusionpracticeasitrelatestoLewisantibodies.3݌$$ Ќ  "3 "  32#  13  .3  0    Statetheantibodyclass,reactivityandclinicalsignificanceofPantibodies. h 3݌p$$ Ќ  "3 "  32#  14  .3  0    StatetwosubstancesusedtoinhibitantiP1.3 ݌\$$ Ќ  "3"  32#  15  .3  0    StatetheprincipleoftheP1neutralization/inhibitiontest.0`$$3݌H`$`$ Ќ  "3"  32#  16  .3  0    Statetheantibodyclass,reactivityandclinical_signifcance_ԀofMandNantibodies.3݌4$$ Ќ  "3"  3-2#  17  .3  0    DescribehowacidifyingtheserumaffectsantibodiestoM.3-Z݌x $$ Ќ  "3"  312#  18  .3  0    Define"dosageaffect"asitrelatestoantigen/antibodyreactions.31^݌d $$ Ќ  "3"  3>2#  19  .3  0    NametheantiNlectin.3>k݌P$$ Ќ  "3"  32#  20  .3  0    Statetheantibodyclass,reactivityandclinicalsignificanceofS,sandUantibodies.3L݌<$$ Ќ  "3"  3A2#  21  .3  0    NamethehighincidenceantigenwhichblackindividualsoftheSsphenotypemayalsobe ( negativefor.3An݌$$ Ќ  "3"  32#  22  .3  0    Explainwhyanti_Lua_doesnotcause_HDN_.0$$3݌$$ Ќ  "3"  32#  23  .3  0    DescribethecharacteristicagglutinationreactiondemonstratedbyLutheranantibodies.3݌$$ Ќ  "3"  32#  24  .3  0    Statetheantibodyclassand_immunogenicity_Ԁofanti_Lua_andanti_Lub_.3'݌ $$ Ќ  "3"  3u 2#  25  .3  0    Describethe_immunogenicity_Ԁofthe_Kell_Ԁantigen.0$$ `   0$$3u ݌ l!$$ Ќ  "3"  3!2#  26  .3  0    Describetherelationshipof_Kpa_,_Kpb_,_Jsa_and_Jsb_withthe_Kell_Ԁbloodgroupsystem.3!"݌!X"$$ Ќ  "3"  3#2#  27  .3  0    Describethemethodutilizedtodetectother_alloantibodies_ԀwhenaDuffyantibodyispresent. $ 3##݌"D #$$ Ќ  "3"  3%2#  28  .3  0    Statethediseasefromwhichpeopleofthe_Fy_Ԁ(ab)phenotypeareresistantto.3%F%݌#0!$$$ Ќ  "3"  3Y&2#  29  .3  0    Statethereasonfreshserummaybethespecimenofchoicewhen_Kidd_Ԁantibodiesaresuspected.3Y&&݌t$"%$$ Ќ  "3"  3'2#  30  .3  0    Describethedangersinvolvedduringtransfusionifa_Kidd_Ԁantibodygoesundetected.3''݌`%#&$$ Ќ  "3"  3(2#  31  .3  0    Listfouradditionalbloodgroupsystemsmaycauseproductionofunexpectedantibodies0!$$0$!$!$0@$p(#p(#0@$(#(#3( )݌L&#'$$$$ Ќ  0  andwhytheseantibodiesareinfrequentlyencountered.0`$$8'$(`$`$ "3"  3*2#  32  .3  0    Nametheonlysexlinkedbloodgroup.3**݌$(%)$$ Ќ  "3 "  3+2#  33  .3  0    Describethedifficultyofworkingupanantibodyandfindingbloodforindividuals0!$$0$!$!$0@$p(#p(#0@$(#(# @$ 3++݌)&*$$$$ Ќ    withantibodiestohighincidenceantigens. )'+ "3!"  3x-2#  34  .3  0    Describewhatismeantby_HTLA_Ԁantibodiesandthetypesofproblemstheycausein0!$$0$!$!$0@$p(#p(#0@$(#(#3x--݌*(,$$$$ Ќ  ݀  serologicaltesting.0 0 $ $0X$$0X$X$0$$0`$$+|)-`$`$ "3""  3/2#  35  .3  0    Describetheclassictypeagglutinationreactionseenwith_Sda_antibodies.3//݌,h*.$$ Ќ  "3#"  302#  36  .3  0    Statetheprincipleoftheprocedureusedtoneutralize_Sda_antibodies.30,1݌-T+/$$ Ќ  "3$"  3722#  37  .3  0    Explainwhyantibodiestolowincidenceantigensdonotcausemuchofaproblem0!$$.372d2݌.@,0!$!$ Ќ  "3%"  3e32#  38  .3  0    DescribetheBgantigensandtheproblems_the_Ԁantibodiescauseinserologicaltesting. ! #XpXXXpR#